DUBLIN--(BUSINESS WIRE)--The "Pancreatic Fistula Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.
The pancreatic fistula treatment market stood at US$ 2,098.16 Mn in 2021 and projected to exhibit compound annual growth rate (CAGR) of 5.7% during the forecast period from 2022 to 2030.
The International Study Group for Pancreatic Fistulas (ISGPF), defines post-operative pancreatic fistula as 'external fistula with a drain output of any measurable volume after post-operative day three with an amylase level greater than three times the upper limit of the normal serum value'.
Based on the clinical impact of the fistula on the patient's hospital stay duration and treatment outcome, pancreatic fistula is categorized into grade A, B and C. Acute and chronic pancreatitis are the major causative factors for pancreatic fistula (55%) followed by iatrogenic factors such as surgery, percutaneous drainage of pseudocysts, and biopsy (35%), and in rare cases trauma (10%).
Administration of total parenteral nutrition and somatostatin analogs are the common measures used for treating pancreatic fistulas, followed by surgical intervention through ERCP and stenting; indicating unavailability of exclusive treatment option (either drug or device) specifically addressing pancreatic fistula. In the future, as the purview of minimally invasive procedures further proliferates the market may witness the emergence of new avenues.
Higher Adoption of Surgical Techniques for Pancreatic Fistula Treatment to Drive Market Growth
In 2021, surgical devices segment dominated the market owing to comparatively higher adoption of medical devices to diagnose and treat pancreatic fistula. In addition, extensive use of sphincterotome, biliary & pancreatic stents, guidewires, balloons, and cannulae while performing ERCP to manage pancreatic fistula is supporting the dominance of the ERCP devices segment.
Total parenteral nutrition segment dominated the drugs segment attributed to augmented demand for parenteral nutrition products including single dose amino acid solution, carbohydrates, parenteral lipid emulsion, trace elements, vitamins, and minerals as it suppresses production of pancreatic enzymes by restricting the oral intake of food and maintains the nutrition of the patient.
Increasing launches of generic drugs & pipeline of octreotide drugs in clinical trials are expected to support the market growth of drugs segment in the near future.
Increasing Healthcare Infrastructure in Asia Pacific to Drive the Growth during the forecast period
In 2021, North America accounted for the largest share in global pancreatic fistula treatment market, due to key driving factors such as rising prevalence of pancreatic cancer and pancreatic neuroendocrine tumors.
With the growing incidences of pancreatic fistula, more number of research studies are being carried out in the region to enhance the usage of endotherapy to minimize the complication of pancreatic fistulae. High funding for R&D from the U.S. Federal Government coupled with presence of major medical device companies in the region would assist North America maintain its pole position during the forecast period.
Asia Pacific emerged as the fastest growing region in the global pancreatic fistula treatment market owing to growing geriatric population susceptible to pancreatic cancer, adenocarcinoma, pancreatic neuroendocrine tumors and other gastrointestinal and lifestyle diseases.
Growing healthcare infrastructure for efficient and preventive pancreatic surgeries will increase the demand for endoscopic retrograde cholangiopancreatography (ERCP) devices for the management of pre and post-operative complications related to pancreatic surgeries.
Market is studied in order to understand the current and future market trends in the pancreatic fistula treatment market. The market is estimated by providing the compounded annual growth rate (CAGR) and data forecast from 2022 to 2030.
Product portfolio provided in the report gives information of the drugs and the surgical devices used in the treatment of pancreatic fistula. Strategic acquisition, merger and collaboration among the key players for developing innovative devices mentioned in the business strategy section.
The key players currently engaged in the pancreatic fistula treatment market are Cook Medical, Inc., CONMED Corporation, Fresenius Kabi AG, B. Braun Melsungen Ag, Becton Dickinson & Company, Medtronic plc, Novartis AG and Others.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Pancreatic Fistula Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Pancreatic Fistula Treatment market?
- Which is the largest regional market for Pancreatic Fistula Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Pancreatic Fistula Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Pancreatic Fistula Treatment market worldwide?
Company Profiles
- Cook Medical Inc.
- CONMED Corporation
- Fresenius Kabi AG
- B. Braun Melsungen Ag
- Becton Dickinson & Company
- Medtronic plc
- Novartis AG
Key Topics Covered:
1. Preface
1.1. Report Description
1.2. Market Segmentation
1.3. Research Methodology
2. Executive Summary
2.1. Market Snapshot: Global Pancreatic Fistula Treatment Market
2.2. Global Pancreatic Fistula Treatment Market, By Treatment, 2021 (US$ Million)
2.3. Global Pancreatic Fistula Treatment Market, By Geography, 2021 (US$ Million)
2.4. Impact of Covid 19
2.5. Attractive Investment Proposition by Geography, 2021
2.6. Competitive Analysis
2.6.1. Market Positioning of Key Pancreatic Fistula Treatment Market Vendors
2.6.2. Strategies Adopted by Pancreatic Fistula Treatment Market Vendors
2.6.3. Key Industry Strategies
3. Pancreatic Fistula Treatment Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Pancreatic Fistula Treatment Market Value, 2020 - 2030, (US$ Million)
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.2. Market Restraints
3.3.3. Key Challenges
3.3.4. Key Opportunities
3.4. Impact Analysis of Drivers and Restraints
3.5. See-Saw Analysis
3.6. Porter's Five Force Model
3.7. PESTEL Analysis
4. Pancreatic Fistula Treatment Market: By Treatment, 2020-2030, USD (Million)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. Drugs
4.3.1.1. Octreotide
4.3.1.2. Total Parenteral Nutrition (TPN)
4.3.2. Devices
4.3.2.1. Fibrin Sealant
4.3.2.2. Endoscopic Ultrasound (EUS) Guided Devices
4.3.2.3. Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices
4.3.2.3.1. Sphincterotome
4.3.2.3.2. Biliary & Pancreatic Stents
4.3.2.3.3. Accessories (Guidewires, Balloons & Cannulae)
4.3.2.4. Surgical Drainage Devices
For more information about this report visit https://www.researchandmarkets.com/r/c7lm35
